Blood · 2012 · 313 citations · 79 references
MedicineOncologyPediatricsChemotherapyPediatric HematologyPediatric OncologyPediatric ChemotherapyPediatric LeukemiasRefractory Childhood CancerRelapsed DiseaseAcute Lymphoblastic Leukemia TreatmentRelapsed Acute Lymphoblastic LeukemiaRelapsed Leukemia
The most common cause of treatment failure in childhood acute lymphoblastic leukemia (ALL) remains relapse, occurring in ~ 15%-20% of patients. Survival of relapsed patients can be predicted by site of relapse, length of first complete remission, and immunophenotype of relapsed ALL. BM and early relapse (< 30 months from diagnosis), as well as T-ALL, are associated with worse prognosis than isolated extramedullary or late relapse (> 30 months from diagnosis). In addition, persistence of minimal residual disease (MRD) at the end of induction or consolidation therapy predicts poor outcome because children with detectable MRD are more likely to relapse than those in molecular remission, even after allogeneic hematopoietic stem cell transplantation. We offer hematopoietic stem cell transplantation to any child with high-risk features because these patients are virtually incurable with chemotherapy alone. By contrast, we treat children with first late BM relapse of B-cell precursor ALL and good clearance of MRD with a chemotherapy approach. We use both systemic and local treatment for extramedullary relapse, mainly represented by radiotherapy and, in case of testicular involvement, by orchiectomy. Innovative approaches, including new agents or strategies of immunotherapy, are under investigation in trials enrolling patients with resistant or more advanced disease.
79
Effectiveness of Donor Natural Killer Cell Alloreactivity in Mismatched Hematopoietic Transplants
Loredana Ruggeri, Marusca Capanni, Elena Urbani et al. · Science · 2002 · 3.4K citations
Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody
Ralf C. Bargou, Eugen Leo, Gerhard Zugmaier et al. · Science · 2008 · 1.1K citations
Life Sciences, Immunology, Oncology +17
Max S. Topp, Peter Kufer, Nicola Gökbuget et al. · Journal of Clinical Oncology · 2011 · 913 citations · Full text
Medicine, Hematology, Oncology +16
Genomic Analysis of the Clonal Origins of Relapsed Acute Lymphoblastic Leukemia
Charles G. Mullighan, Letha A. Phillips, Xiaoping Su et al. · Science · 2008 · 810 citations · Full text